|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FBF1 |
Gene summary for FBF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FBF1 | Gene ID | 85302 |
| Gene name | Fas binding factor 1 | |
| Gene Alias | Alb | |
| Cytomap | 17q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q8TES7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 85302 | FBF1 | LZE7T | Human | Esophagus | ESCC | 2.91e-04 | 2.54e-01 | 0.0667 |
| 85302 | FBF1 | LZE21D1 | Human | Esophagus | HGIN | 5.11e-03 | 4.43e-01 | 0.0632 |
| 85302 | FBF1 | LZE22T | Human | Esophagus | ESCC | 3.24e-02 | 1.80e-01 | 0.068 |
| 85302 | FBF1 | LZE24T | Human | Esophagus | ESCC | 1.09e-13 | 2.66e-01 | 0.0596 |
| 85302 | FBF1 | LZE21T | Human | Esophagus | ESCC | 3.64e-02 | 1.94e-01 | 0.0655 |
| 85302 | FBF1 | P1T-E | Human | Esophagus | ESCC | 1.60e-05 | 2.28e-01 | 0.0875 |
| 85302 | FBF1 | P2T-E | Human | Esophagus | ESCC | 1.59e-16 | 2.15e-01 | 0.1177 |
| 85302 | FBF1 | P4T-E | Human | Esophagus | ESCC | 5.42e-09 | 1.10e-01 | 0.1323 |
| 85302 | FBF1 | P5T-E | Human | Esophagus | ESCC | 9.05e-07 | 8.43e-02 | 0.1327 |
| 85302 | FBF1 | P8T-E | Human | Esophagus | ESCC | 7.95e-04 | 7.52e-02 | 0.0889 |
| 85302 | FBF1 | P9T-E | Human | Esophagus | ESCC | 2.25e-02 | 5.32e-02 | 0.1131 |
| 85302 | FBF1 | P10T-E | Human | Esophagus | ESCC | 4.00e-13 | 1.22e-01 | 0.116 |
| 85302 | FBF1 | P12T-E | Human | Esophagus | ESCC | 2.78e-17 | 1.18e-01 | 0.1122 |
| 85302 | FBF1 | P15T-E | Human | Esophagus | ESCC | 1.75e-08 | 1.22e-01 | 0.1149 |
| 85302 | FBF1 | P16T-E | Human | Esophagus | ESCC | 6.15e-14 | 1.66e-01 | 0.1153 |
| 85302 | FBF1 | P20T-E | Human | Esophagus | ESCC | 2.63e-28 | 5.96e-01 | 0.1124 |
| 85302 | FBF1 | P21T-E | Human | Esophagus | ESCC | 1.31e-04 | 1.29e-01 | 0.1617 |
| 85302 | FBF1 | P22T-E | Human | Esophagus | ESCC | 2.08e-19 | 2.75e-01 | 0.1236 |
| 85302 | FBF1 | P23T-E | Human | Esophagus | ESCC | 1.48e-03 | 6.76e-02 | 0.108 |
| 85302 | FBF1 | P26T-E | Human | Esophagus | ESCC | 1.03e-04 | 5.83e-02 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000716320 | Esophagus | ESCC | establishment or maintenance of cell polarity | 143/8552 | 218/18723 | 2.05e-09 | 4.65e-08 | 143 |
| GO:003001018 | Esophagus | ESCC | establishment of cell polarity | 96/8552 | 143/18723 | 1.69e-07 | 2.67e-06 | 96 |
| GO:009016216 | Esophagus | ESCC | establishment of epithelial cell polarity | 25/8552 | 31/18723 | 7.13e-05 | 5.38e-04 | 25 |
| GO:003432918 | Esophagus | ESCC | cell junction assembly | 227/8552 | 420/18723 | 3.06e-04 | 1.83e-03 | 227 |
| GO:004521620 | Esophagus | ESCC | cell-cell junction organization | 114/8552 | 200/18723 | 8.04e-04 | 4.16e-03 | 114 |
| GO:004329718 | Esophagus | ESCC | apical junction assembly | 48/8552 | 78/18723 | 3.45e-03 | 1.41e-02 | 48 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FBF1 | SNV | Missense_Mutation | c.319N>G | p.Lys107Glu | p.K107E | Q8TES7 | protein_coding | deleterious(0) | benign(0.116) | TCGA-A2-A25D-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| FBF1 | SNV | Missense_Mutation | c.1297N>A | p.Glu433Lys | p.E433K | Q8TES7 | protein_coding | tolerated(0.18) | benign(0.011) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FBF1 | SNV | Missense_Mutation | c.85N>C | p.Glu29Gln | p.E29Q | Q8TES7 | protein_coding | tolerated(0.09) | possibly_damaging(0.801) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FBF1 | SNV | Missense_Mutation | c.715A>C | p.Lys239Gln | p.K239Q | Q8TES7 | protein_coding | tolerated(0.2) | benign(0.124) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FBF1 | SNV | Missense_Mutation | c.1174C>T | p.Pro392Ser | p.P392S | Q8TES7 | protein_coding | tolerated(0.28) | benign(0.439) | TCGA-AR-A0TZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Doxorubicin | PD | |
| FBF1 | SNV | Missense_Mutation | novel | c.2021N>T | p.Ser674Leu | p.S674L | Q8TES7 | protein_coding | deleterious(0.05) | possibly_damaging(0.683) | TCGA-B6-A0I1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| FBF1 | SNV | Missense_Mutation | rs373558594 | c.428N>T | p.Pro143Leu | p.P143L | Q8TES7 | protein_coding | tolerated(0.06) | benign(0.383) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| FBF1 | SNV | Missense_Mutation | rs760384213 | c.745N>T | p.Arg249Cys | p.R249C | Q8TES7 | protein_coding | deleterious(0) | possibly_damaging(0.731) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FBF1 | SNV | Missense_Mutation | rs540051078 | c.1607N>T | p.Ser536Leu | p.S536L | Q8TES7 | protein_coding | tolerated(0.15) | benign(0.007) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
| FBF1 | SNV | Missense_Mutation | novel | c.2632N>T | p.Ala878Ser | p.A878S | Q8TES7 | protein_coding | tolerated(0.11) | benign(0.191) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |